Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Overview
Silo Pharma Inc. is a developmental stage biopharmaceutical company that develops innovative therapeutics by merging traditional formulations with advanced psychedelic research. The company is dedicated to addressing underserved conditions including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Through its unique approach, Silo Pharma focuses on both traditional and psychedelic treatment modalities to provide novel solutions where unmet medical needs persist.
Therapeutic Programs and Drug Delivery Systems
Silo Pharma is actively progressing a broad portfolio of therapeutic programs, each aimed at targeting specific medical indications:
- SPC-15: An intranasal serotonin 5-HT4 receptor agonist designed for treating post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders. Leveraging biomarker-driven research, SPC-15 utilizes a non-invasive delivery method for rapid therapeutic onset.
- SP-26: A ketamine-based, time-release polymer implant developed to manage chronic pain conditions such as fibromyalgia. This innovative implant is designed to provide consistent, dosage-controlled pain relief through a minimally invasive subcutaneous procedure.
- Additional programs include preclinical assets targeting CNS disorders such as Alzheimer’s disease and multiple sclerosis, which further underscore the company’s comprehensive approach to neurological challenges.
Research Collaborations and Intellectual Property
Silo Pharma conducts its research and development through strategic collaborations with world-class medical research partners and universities. By partnering with renowned institutions, the company ensures robust scientific validation and leverages cutting-edge research in its clinical development pathways. An important component of its business model is a focused intellectual property strategy that reinforces patent protection for its lead assets, thereby safeguarding its innovations in drug delivery and therapeutic formulations.
Innovation in Drug Formulations and Delivery
At the core of Silo Pharma's strategy is the development of novel drug delivery systems. Its innovative approach encompasses:
- The use of intranasal formulations which provide a convenient and rapid therapeutic option for stress-related disorders.
- Advanced polymer-based implants ensuring sustained and controlled drug release, which is critical for chronic conditions such as fibromyalgia.
- Exploration of dual-action pharmacological approaches combining different receptor targets to enhance therapeutic efficacy without compromising safety.
Market Position and Operational Philosophy
Although Silo Pharma operates at a developmental stage, its scientifically rigorous and research-driven approach places it strategically within the biopharmaceutical industry. The company prioritizes collaborations with leading research institutions and maintains a strong emphasis on ensuring that its technologies meet regulatory safety profiles. This methodical progression from preclinical research through to clinical evaluation highlights its commitment to developing treatments that have the potential to transform patient care in areas with limited therapeutic options.
Commitment to Research Excellence
Silo Pharma is anchored on principles of expertise, authoritativeness, and trustworthiness. Its research is designed to resolve significant medical challenges with precise, mechanism-based therapies. By continuously enhancing its array of novel formulations and robust drug delivery systems, the company exemplifies a balanced approach, integrating rigorous scientific research with practical therapeutic solutions.
Silo Pharma, Inc. (OTCQB: SILO) has entered a Scientific Research Agreement with the University of California San Francisco (UCSF) to explore the effects of psilocybin on inflammatory markers in patients with Parkinson's, Bipolar disorder, and chronic back pain. This agreement will utilize four other planned clinical trials by UCSF. CEO Eric Weisblum emphasized the potential of psilocybin to reduce inflammation related to these conditions, which may improve treatment outcomes. The study will be conducted at UCSF's Translational Psychedelic Research Program, focusing on the impact of psychedelics on various disorders.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its initial application to list on the NASDAQ Capital Market. This follows the board's prior approval to commence the up-listing process. The NASDAQ listing is contingent upon meeting regulatory requirements and acceptance by NASDAQ, which cannot be assured. CEO Eric Weisblum emphasized that a NASDAQ listing aims to enhance investor liquidity, attract institutional investors, and improve the company's visibility. Silo Pharma focuses on developing psychedelic therapies for conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its investigator-led study using Psilocybin for treating Parkinson’s disease for ethics board review in the Netherlands. CEO Eric Weisblum expressed satisfaction with this milestone and anticipates sharing more details with the scientific community and shareholders.
Silo Pharma is focused on merging traditional therapeutics with psychedelic research to assist patients suffering from conditions like depression, PTSD, and rare neurological disorders.
Silo Pharma (OTCQB: SILO) has announced a joint venture with Zylo Therapeutics to develop a sustained-release topical delivery system for ketamine and psilocybin. This collaboration aims to address the needs of patients with dysphagia, particularly those dealing with Alzheimer’s and Parkinson’s diseases. The ZTI’s Z-pod technology will enable the controlled delivery of these psychedelics, potentially reducing hallucinogenic effects while exploring their safety and efficacy. This initiative aligns with Silo Pharma's mission to innovate therapeutic solutions.
Silo Pharma, Inc. (OTCQB: SILO) announced its Board of Directors' unanimous decision to uplist to the NASDAQ. CEO Eric Weisblum emphasized that this move aims to enhance visibility and attract institutional investors, fostering long-term shareholder value. The uplisting is contingent upon meeting NASDAQ's listing requirements and securing approval. Silo Pharma focuses on developing psilocybin-based therapeutics for mental health issues and neurological disorders.
Silo Pharma, Inc. (OTCQB: SILO), a biopharmaceutical company focusing on psilocybin therapy, has finalized a sublicense agreement related to its provisional patent for CNS homing peptides aimed at treating pain from neuroinflammation in cancer patients. CEO Eric Weisblum expressed enthusiasm for the collaboration and emphasized the company's commitment to creating shareholder value while developing innovative therapeutics. The news comes on the heels of an earlier Letter of Intent from February, highlighting Silo's strategic growth.
Silo Pharma has entered an exclusive option agreement with the University of Maryland to investigate novel joint-homing peptides aimed at treating inflammation related to autoimmune diseases, specifically rheumatoid arthritis. These peptides could enhance drug delivery directly to affected joints, potentially increasing therapeutic efficacy while minimizing systemic toxicity. Silo's CEO emphasized the potential of this technology as a revolutionary drug delivery platform that meets the need for innovative treatments for patients with rare diseases.
Silo Pharma, a biopharmaceutical company, announced that CEO Eric Weisblum will present at Proactive's One2One Virtual Investor Forum on February 23, 2021, at 1 p.m. EST. The event is expected to reach Proactive's 20,000 YouTube subscribers and will be broadcasted globally. Silo Pharma focuses on merging traditional therapeutics with psychedelic research to address conditions such as depression, PTSD, and Parkinson's disease. The presentation will include a Q&A session and will be made available online after the event.
Silo Pharma has signed a Master License Agreement with the University of Maryland Baltimore to license innovative Central nervous system-homing peptides aimed at treating multiple sclerosis and other neuroinflammatory disorders. This agreement follows preclinical studies that support the peptide's efficacy. CEO Eric Weisblum emphasized Silo's commitment to merging traditional therapeutics with psychedelic research, suggesting potential benefits for patients with neurological conditions.
Silo Pharma, a developmental stage biopharmaceutical company, has secured $4.275 million through Securities Purchase Agreements for its Series C Preferred Stock. The financing involves issuing 4,276 shares and warrants for 14,253,333 shares of common stock with an exercise price of $0.30 per share. The funds will support the development of psychedelic therapeutics for conditions like depression and PTSD. The transaction, expected to close by February 11, 2021, reflects investor confidence in Silo's strategic growth plan.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What is the core focus of Silo Pharma Inc?
How does Silo Pharma generate its revenue?
What are the key therapeutic programs of Silo Pharma?
What is unique about Silo Pharma's approach to drug delivery?
Who are Silo Pharma's research partners?
How does Silo Pharma protect its intellectual property?
What are the potential benefits of SPC-15?
In what ways does Silo Pharma demonstrate expertise in the industry?
